Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

NCT04279847 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04279847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04279847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Lead sponsor
Incyte Corporation
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 23, 2021
Completion date
April 30, 2027
Enrollment
140 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

et (essential thrombocythemia), myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm overlap syndrome, myelofibrosis, myeloproliferative neoplasm, relapsed or refractory primary myelofibrosis, secondary myelofibrosis (post-polycythemia vera myelofibrosis, post-essential thrombocythemia myelofibrosis)